Forte Biosciences Soars 39% After Argenx Announces Acquisition of Atopic Dermatitis Biotech

The Quick Take

• Forte Biosciences (FBRX) shares surged 39% after Belgian immunology company argenx announced a deal to acquire the atopic dermatitis-focused biotech
• The acquisition extends argenx's immunology portfolio into dermatology, where FBRX's pipeline competes in the competitive atopic dermatitis treatment space
• Watch for deal terms disclosure, competing bidder interest, and regulatory clearance timeline given FBRX's clinical-stage asset value

Forte Biosciences shares surged approximately 39 percent after specialty immunology company argenx announced an agreement to acquire the biotech, which is developing treatments for inflammatory skin conditions including moderate-to-severe atopic dermatitis. The acquisition represents argenx's strategic move to diversify its pipeline beyond its core neurology and immunology assets, entering the high-value dermatology market where atopic dermatitis treatments represent a multi-billion dollar annual revenue opportunity. Argenx's existing efgartigimod platform targets FcRn-mediated autoimmune conditions; FBRX's clinical programs add a complementary mechanism to the combined portfolio.

The 39 percent premium on FBRX shares reflects the acquisition announcement delivering substantial value crystallization for Forte's shareholders, who had seen the stock trade at depressed levels during the biotech sector's funding-constrained period. For argenx, the acquisition cost must be weighed against the strategic value of FBRX's clinical data, which could accelerate argenx's position in dermatology against Dupixent — Regeneron and Sanofi's blockbuster atopic dermatitis treatment — and competing IL-31 and IL-4 pathway inhibitors. Argenx's balance sheet strength, having generated significant revenue from its approved FcRn inhibitor Vyvgart, gives it the financial capacity to execute bolt-on biotech acquisitions.

Watch for deal terms disclosure including the acquisition price and any milestone payments tied to FBRX's clinical program progression; the 39 percent move implies the deal price was significantly above FBRX's pre-announcement trading range. Any competing bidder interest from larger dermatology players including AbbVie, Eli Lilly, or Pfizer — all of whom have strategic interest in expanding their inflammatory skin disease portfolios — would create upward pressure on the deal price. Regulatory clearance from the FTC is the primary completion risk, though the transaction is unlikely to create market concentration concerns given the pre-commercial status of FBRX's assets.

Synthesized from 1 source.